Holen Sie sich die Stockscreener-App
2.60
10.32%
-0.21
Schlusskurs vom Vortag:
$2.81
Offen:
$2.78
24-Stunden-Volumen:
3,964
Relative Volume:
0.05
Marktkapitalisierung:
$13.49M
Einnahmen:
$29.57M
Nettoeinkommen (Verlust:
$-34.68M
KGV:
-0.00367
EPS:
-708.7214
Netto-Cashflow:
$-7.58M
1W Leistung:
-16.00%
1M Leistung:
-10.00%
6M Leistung:
-92.73%
1J Leistung:
-96.88%
1-Tages-Spanne:
$2.76
$2.85
1-Wochen-Bereich:
$2.70
$3.07
52-Wochen-Spanne:
$2.12
$88.77
Jaguar Health Inc Stock (JAGX) Company Profile
Firmenname
Jaguar Health Inc
Sektor
Branche
Telefon
415-371-8300
Adresse
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Compare JAGX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
2.8002 | 14.45M | 29.57M | -34.68M | -7.58M | -708.72 |
VRTX
Vertex Pharmaceuticals Inc
|
517.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.56 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.15 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.44 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.69 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Eingeleitet | Rodman & Renshaw | Buy |
Jaguar Health Inc Aktie (JAGX) Neueste Nachrichten
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health Company Profile & Introduction - Moomoo
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Inc (JAGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBITDA forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health (JAGX) Announces Conversion of Series O Convertibl - GuruFocus
Jaguar Health Converts Series O Preferred Stock; Advances Crofelemer Program for Rare Intestinal Failure Diseases - Minichart
Series O preferred conversion at Jaguar Health (NASDAQ: JAGX) - Stock Titan
Price to sales forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - ACCESS Newswire
Jaguar Health's one-time stock dividend converts into 3.209 shares - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health Inc (JAGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jaguar Health (JAGX) Submits New Drug Application for Canalevia-CA1 - GuruFocus
Jaguar Health submits drug application for dog diarrhea treatment By Investing.com - Investing.com Australia
Jaguar Health submits drug application for dog diarrhea treatment - Investing.com UK
Jaguar Health explores strategic options, shares react ahead of Nasdaq investor forum - AD HOC NEWS
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health seeks full FDA approval for dog diarrhea drug - Stock Titan
Jaguar Health Explores Strategic Alternatives Ahead of NDA Filing for Crofelemer Rare Intestinal Failure Drug - Minichart
Jaguar Health (NASDAQ: JAGX) updates release on strategic alternatives - Stock Titan
Jaguar Health (JAGX) Explores Strategic Alternatives for Stockho - GuruFocus
Jaguar Health Explores Strategic Alternatives Ahead of NDA for Rare Intestinal Failure Drug Crofelemer in $1.1B Market 1 – Minichart - Minichart
Jaguar Health reviews strategic alternatives ahead of Crofelemer NDA filing - MSN
Jaguar Health explores strategic alternatives to maximize value By Investing.com - Investing.com South Africa
Jaguar Health explores strategic alternatives to maximize value - Investing.com
Form 8K Jaguar Health Inc For: 22 June By Investing.com - Investing.com Nigeria
Jaguar Health launches strategic review aligned with targeted NDA for crofelemer - TradingView
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
Jaguar Health starts strategic review as crofelemer NDA work nears - Stock Titan
Jaguar Health Inc (JAGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention - ACCESS Newswire
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health - Florida Hospital News and Healthcare Report
Jaguar Health, Inc. Announces Material Definitive Agreements and Exchange with Streeterville Capital and Uptown Capital – SEC 8-K Filing Summary – Minichart - Minichart
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Jaguar Health Amends Royalty Deals, Extends Note Maturity, and Executes Three Preferred-for-Common Exchanges - TradingView
Finanzdaten der Jaguar Health Inc-Aktie (JAGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.95%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):